Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sung, Hwa Jung | - |
dc.contributor.author | Lee, Se Ryeon | - |
dc.contributor.author | Choi, In Keun | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Kim, Hyeoung-Joon | - |
dc.contributor.author | Yhim, Ho-Young | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.date.accessioned | 2021-09-05T00:45:30Z | - |
dc.date.available | 2021-09-05T00:45:30Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0001-5792 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/96128 | - |
dc.description.abstract | Aim: Chronic myelogenous leukemia (CML) chronic phase (CP) patients cannot tolerate a standard dose (400 mg/day) of imatinib mesylate (IM), sometimes needing a reduced dose. This study aimed to find convenient clinical indexes, rather than plasma trough levels of IM, to define the appropriate IM dosage. Methods: Seventy CML CP patients who experienced an IM dose reduction, or a temporary cessation, were enrolled from 2002 to 2010. The IM treatment was resumed and maintained at either >= 400 mg in 25 patients (35.7%; group >= 400 mg) or at <= 300 mg in 45 patients (64.3%; group <= 300 mg). The various clinical characteristics of these patients were evaluated. The plasma trough level of IM was monitored in 20 patients from group <= 300 mg. Results: Via multivariate analysis, the IM dosage divided by the body surface area (BSA) was an important index, presupposing a complete cytogenetic response at 12 months (CCyR12). Patients with IM/BSA >206.7 mg/m(2) showed a higher probability of CCyR12 than others. The IM/BSA (221.7 mg/m(2)) in group <= 300 mg was higher than in group >= 400 mg (207.6 mg/m(2)). The sustained response and survival rate of group <= 300 mg was comparable to that of group >= 400 mg. The plasma trough level of IM was significantly correlated with the IM/BSA. Conclusion: Our study suggests that IM dose adjustments, based on IM/BSA, could improve the clinical outcomes in CML CP patients. (C) 2015 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | CHRONIC MYELOID-LEUKEMIA | - |
dc.subject | CHRONIC MYELOGENOUS LEUKEMIA | - |
dc.subject | TROUGH CONCENTRATION | - |
dc.subject | EFFICACY | - |
dc.subject | SAFETY | - |
dc.title | Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Se Ryeon | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.contributor.affiliatedAuthor | Kim, Byung Soo | - |
dc.identifier.doi | 10.1159/000369444 | - |
dc.identifier.scopusid | 2-s2.0-84927929799 | - |
dc.identifier.wosid | 000356978200010 | - |
dc.identifier.bibliographicCitation | ACTA HAEMATOLOGICA, v.134, no.1, pp.59 - 68 | - |
dc.relation.isPartOf | ACTA HAEMATOLOGICA | - |
dc.citation.title | ACTA HAEMATOLOGICA | - |
dc.citation.volume | 134 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 59 | - |
dc.citation.endPage | 68 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | CHRONIC MYELOID-LEUKEMIA | - |
dc.subject.keywordPlus | CHRONIC MYELOGENOUS LEUKEMIA | - |
dc.subject.keywordPlus | TROUGH CONCENTRATION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Chronic myelogenous leukemia | - |
dc.subject.keywordAuthor | Imatinib mesylate | - |
dc.subject.keywordAuthor | Body surface area | - |
dc.subject.keywordAuthor | Complete cytogenetic response | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.